Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

DAB2 (disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila))

Written2009-05Maurizio Orlandini
Department of Molecular Biology, Via Fiorentina 1, 53100 - Siena, Italy

(Note : for Links provided by Atlas : click)

Identity

Alias_namesdisabled (Drosophila) homolog 2 (mitogen-responsive phosphoprotein)
disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)
Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)
Alias_symbol (synonym)DOC-2
HGNC (Hugo) DAB2
LocusID (NCBI) 1601
Atlas_Id 40258
Location 5p13.1  [Link to chromosome band 5p13]
Location_base_pair Starts at 39371776 and ends at 39425335 bp from pter ( according to hg19-Feb_2009)  [Mapping DAB2.png]
Local_order The complement factor 9 (C9) gene is located at the 3'-end of the DAB2 gene.
Fusion genes
(updated 2016)
ACTN4 (19q13.2) / DAB2 (5p13.1)CSF3R (1p34.3) / DAB2 (5p13.1)DAB2 (5p13.1) / DAB2 (5p13.1)
DAB2 (5p13.1) / ZIM2 (19q13.43)PAIP1 (5p12) / DAB2 (5p13.1)PIK3C3 (18q12.3) / DAB2 (5p13.1)
Note DAB2 was first identified as DOC-2, for differentially expressed in ovarian carcinoma, and subsequently as a protein whose phosphorylation is stimulated by CSF-1.

DNA/RNA

Description The DAB2 gene consists of 15 exons and 14 introns spanning in a region of 35 kb in size.
Transcription The putative DAB2 promoter was identified within a 420-bp sequence upstream of the exon1/intron1 junction. DAB2 is alternatively spliced to generate several transcripts and proteins. The transcript has been detected in spleen, thymus, prostate, testis, small intestine, and abundant in ovary.

Protein

Note DAB2 plays a pivotal role in the control of cellular homeostasis. The adaptor protein DAB2 is implicated in several receptor-mediated signaling pathways, endocytosis, cell adhesive function, hematopoietic cell differentiation, and angiogenesis.
 
  Schematic representation of DAB2 domains. DAB2 possess a highly conserved N-terminal phosphotyrosine-interacting/phosphotyrosine binding domain (PID/PTB), renamed the DAB homology domain, and a C-terminal proline-rich domain (PRD).
Description 770 amino acids, molecular weight 82.5 kDa. DAB2 contains an N-terminal PID/PTB domain (amino acid 42-180) and three C-terminal proline-rich domains (amino acid 619-627, 663-671, and 714-722). A potential actin-binding motif, KKEK is present in the N-terminal domain.
Expression Widely expressed. Cytoplasmic. DAB2 is expressed in many epithelial cell types and was suggested to have a role in epithelial organization. dab2 knock-out mice are embryonic lethal for defective visceral endoderm cell organization. In fact, in dab2 (-/-) mice, the epithelial cells of the early embryos (visceral endoderm) mix within the interior rather then align as a layer covering the inner cell mass. The role of Dab2 in mediating directional trafficking of endocytic proteins to establish apical polarity is suggested as a mechanism for surface positioning of endoderm cells.
Function The PID/PTB and PRD domains of DAB2 associate with several proteins, and these interactions have been shown to modulate protein trafficking, cytoskeleton organization, cell adhesion and migration, and cell signaling of various receptor protein-tyrosine kinases.

  • Cell cycle: DAB2 was identified as a protein phosphorylated in response to mitogenic stimulation by CSF-1. In cells, protein phosphorylation of DAB2 modulates its functional activity. Protein kinase C (PKC) and Cdc2 are the two known DAB2 kinases. The major PKC phosphorylation site has been mapped to Ser24 and it is essential for the inhibitory function of DAB2 in TPA-induced AP-1 gene transcription. DAB2 is differentially phosphorylated during the cell cycle by cdc2, and its phosphorylation promotes the association of DAB2 with Pin1, that regulates the rate of DAB2 dephosphorylation.

  • Vesicle traffic: DAB2 plays a role in linking specific extracellular receptors to the endocytic machinery. DAB2 associates with AP-2-positive clathrin-coated structures, together with endocytosed trans-membrane proteins such as low-density lipoprotein (LDL) receptors and integrins. DAB2 also binds to the actin-based myosin VI, mediating the attachment of cargos to motor proteins and regulating protein trafficking.

  • Signaling pathways:
    - TGFbeta - Dab2 associates with Smad2 and Smad3, by a direct interaction with the PID/PTB domain of Dab2, and with TGFbeta receptor I and TGFbeta receptor II. Thus Dab2 may be an essential component of the TGFbeta signaling pathway allowing the transmission of signals from the TGFbeta receptors to the Smad family of transcriptional activators.
    - WNT - Dab2 associates with Axin and stabilizes its expression by preventing Axin interaction with the LRP5 co-receptor. Thus the interaction of Axin with beta-catenin results stabilized with an increase in beta-catenin degradation and attenuation of Wnt signaling.
    - RAS/RAF/MAPK - In cell culture experiments, a Dab2 over-expression leads to suppression of c-Fos expression and cell growth inhibition without affecting MAPK activity. In vivo studies confirmed a Dab2 role in regulating c-Fos expression. A possible molecular mechanism of action is that Dab2 limits the entry of the activated MAPK into the nucleus. DAB2 can also interact with Grb2 through its PRD. Receptor tyrosine kinase activation by growth factors increases the binding of DAB2 to Grb2, which interrupts the binding of SOS to Grb2 and leads to suppression of ERK activation.

  • Cell adhesion: DAB2 is an adhesion-responsive phosphoprotein and plays a role in cell adhesion and spreading. Ser24 phosphorylation promotes membrane translocation of DAB2 and its interaction with beta3 integrin. DAB2 negatively regulates integrin alphaIIbbeta3 activation, leading to the inhibition of alphaIIbbeta3-mediated fibrinogen adhesion. In cell experiments during TGFbeta-induced epithelial to mesenchymal trans-differentiation (EMT), Dab2 expression is increased and Dab2 binds to beta1 integrin. In these conditions, Dab2 silencing leads to a decrease in cell adherence, inhibition of EMT, and apoptosis.
  • Angiogenesis: DAB2 can bind to Shc3 domain of Src and this interaction results in Src inactivation. DAB2 is expressed in human umbilical vein endothelial cells (HUVEC). By modulating the activation of Src-FAK signaling and MAPK phosphorylation, DAB2 controls endothelial cell migration and differentiation.
  • Homology The Disabled proteins are a family of adapters involved in cellular signaling, oncogenesis, and development. DAB2 is related to Drosophila Disabled and mammalian Dab1, which regulate neuronal development. DAB2 shares 81% identity with the mouse p96/Dab2 protein.

    Implicated in

    Note
    Entity Epithelial ovarian cancer
    Note DAB2 was identified due to the loss of its expression in ovarian cancer cells. Ovarian carcinoma cells transfected with DAB2 showed a reduced growth rate and ability to form tumors in nude mice. Loss of DAB2 expression is not correlated with tumor grade, suggesting that loss of DAB2 expression is an early event in ovarian malignancies and DAB2 behaves as a tumor suppressor.
      
    Entity Prostate cancer
    Note DAB2 is a potent growth inhibitor for prostate cancer cells by suppressing several protein kinase pathways. The PRD of DAB2 is the key functional domain responsible for this activity. It was shown that in prostate cancer cells without endogenous DAB2 expression, a functional motif derived from the PRD of DAB2 conjugated with a delivery system is a potent growth inhibitor.
      
    Entity Breast cancer
    Note DAB2 sensitizes breast cancer cells to cell death upon the loss of cell-matrix attachment by targeting the oncogenic activity of ILK.
      
    Entity Various cancer
    Note Urothelial carcinoma of the bladder, esophageal squamous carcinoma, metastatic pancreatic cancer, colorectal cancer, gestational choriocarcinoma.
    Disease DAB2 expression is down-regulated.
      
    Entity Malignant peripheral nerve sheath tumor, invasive cervical carcinoma
    Note Comparative genomic hybridization (CGH) revealed frequent gains of DAB2.
      

    Bibliography

    Sequence, genomic structure, and chromosomal assignment of human DOC-2.
    Albertsen HM, Smith SA, Melis R, Williams B, Holik P, Stevens J, White R.
    Genomics. 1996 Apr 15;33(2):207-13.
    PMID 8660969
     
    Disabled-2 inactivation is an early step in ovarian tumorigenicity.
    Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX.
    Oncogene. 1999 May 20;18(20):3104-13.
    PMID 10340382
     
    Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation.
    He J, Smith ER, Xu XX.
    J Biol Chem. 2001 Jul 20;276(29):26814-8. Epub 2001 May 18.
    PMID 11359772
     
    Cell cycle-dependent phosphorylation of Disabled-2 by cdc2.
    He J, Xu J, Xu XX, Hall RA.
    Oncogene. 2003 Jul 17;22(29):4524-30.
    PMID 12881709
     
    Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma.
    Hidalgo A, Baudis M, Petersen I, Arreola H, Pina P, Vazquez-Ortiz G, Hernandez D, Gonzalez J, Lazos M, Lopez R, Perez C, Garcia J, Vazquez K, Alatorre B, Salcedo M.
    BMC Cancer. 2005 Jul 9;5:77.
    PMID 16004614
     
    The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway.
    Hocevar BA, Smine A, Xu XX, Howe PH.
    EMBO J. 2001 Jun 1;20(11):2789-801.
    PMID 11387212
     
    Disabled-2 is a negative regulator of integrin alpha(IIb)beta(3)-mediated fibrinogen adhesion and cell signaling.
    Huang CL, Cheng JC, Liao CH, Stern A, Hsieh JT, Wang CH, Hsu HL, Tseng CP.
    J Biol Chem. 2004 Oct 1;279(40):42279-89. Epub 2004 Jul 26.
    PMID 15280374
     
    The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin.
    Jiang Y, Prunier C, Howe PH.
    Oncogene. 2008 Mar 20;27(13):1865-75. Epub 2007 Oct 8.
    PMID 17922036
     
    Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT.
    Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4400-6.
    PMID 17671122
     
    Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor.
    Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, Traub LM.
    EMBO J. 2002 Sep 16;21(18):4915-26.
    PMID 12234931
     
    DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer.
    Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS.
    Oncogene. 1998 May 7;16(18):2381-7.
    PMID 9620555
     
    Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2.
    Morris SM, Cooper JA.
    Traffic. 2001 Feb;2(2):111-23.
    PMID 11247302
     
    Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization.
    Nakagawa Y, Yoshida A, Numoto K, Kunisada T, Wai D, Ohata N, Takeda K, Kawai A, Ozaki T.
    Oncol Rep. 2006 Feb;15(2):297-303.
    PMID 16391845
     
    Morphogenesis of human endothelial cells is inhibited by DAB2 via Src.
    Orlandini M, Nucciotti S, Galvagni F, Bardelli M, Rocchigiani M, Petraglia F, Oliviero S.
    FEBS Lett. 2008 Jul 23;582(17):2542-8. Epub 2008 Jun 26.
    PMID 18582465
     
    Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT).
    Prunier C, Howe PH.
    J Biol Chem. 2005 Apr 29;280(17):17540-8. Epub 2005 Feb 25.
    PMID 15734730
     
    Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion.
    Rosenbauer F, Kallies A, Scheller M, Knobeloch KP, Rock CO, Schwieger M, Stocking C, Horak I.
    EMBO J. 2002 Feb 1;21(3):211-20.
    PMID 11823414
     
    Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2).
    Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX.
    Genomics. 2000 Dec 15;70(3):381-6.
    PMID 11161789
     
    Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells.
    Smith ER, Capo-chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX.
    J Biol Chem. 2001 Dec 14;276(50):47303-10. Epub 2001 Sep 27.
    PMID 11577091
     
    Myosin VI targeting to clathrin-coated structures and dimerization is mediated by binding to Disabled-2 and PtdIns(4,5)P2.
    Spudich G, Chibalina MV, Au JS, Arden SD, Buss F, Kendrick-Jones J.
    Nat Cell Biol. 2007 Feb;9(2):176-83. Epub 2006 Dec 24.
    PMID 17187061
     
    The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer.
    Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT.
    J Biol Chem. 1999 Nov 5;274(45):31981-6.
    PMID 10542228
     
    DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway.
    Wang SC, Makino K, Xia W, Kim JS, Im SA, Peng H, Mok SC, Singletary SE, Hung MC.
    Oncogene. 2001 Oct 18;20(47):6960-4.
    PMID 11687976
     
    Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product.
    Xu XX, Yang W, Jackowski S, Rock CO.
    J Biol Chem. 1995 Jun 9;270(23):14184-91.
    PMID 7775479
     
    Disabled-2 is an epithelial surface positioning gene.
    Yang DH, Cai KQ, Roland IH, Smith ER, Xu XX.
    J Biol Chem. 2007 Apr 27;282(17):13114-22. Epub 2007 Mar 5.
    PMID 17339320
     
    C-Fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development.
    Yang DH, Smith ER, Cai KQ, Xu XX.
    Dev Dyn. 2009 Mar;238(3):514-23.
    PMID 19191218
     
    Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle.
    Zhou J, Fan J, Hsieh JT.
    Cancer Res. 2006 Sep 15;66(18):8954-8.
    PMID 16982733
     
    The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2.
    Zhou J, Hsieh JT.
    J Biol Chem. 2001 Jul 27;276(30):27793-8. Epub 2001 May 22.
    PMID 11371563
     
    Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer.
    Zhou J, Scholes J, Hsieh JT.
    J Biol Chem. 2003 Feb 28;278(9):6936-41. Epub 2002 Dec 8.
    PMID 12473651
     
    The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer.
    Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT.
    Cancer Res. 2005 Nov 1;65(21):9906-13.
    PMID 16267015
     

    Citation

    This paper should be referenced as such :
    Orlandini, M
    DAB2 (disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila))
    Atlas Genet Cytogenet Oncol Haematol. 2010;14(4):365-367.
    Free journal version : [ pdf ]   [ DOI ]
    On line version : http://AtlasGeneticsOncology.org/Genes/DAB2ID40258ch5p13.html


    Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]
      Ovary: Choriocarcinoma


    External links

    Nomenclature
    HGNC (Hugo)DAB2   2662
    Cards
    AtlasDAB2ID40258ch5p13
    Entrez_Gene (NCBI)DAB2  1601  DAB2, clathrin adaptor protein
    AliasesDOC-2; DOC2
    GeneCards (Weizmann)DAB2
    Ensembl hg19 (Hinxton)ENSG00000153071 [Gene_View]  chr5:39371776-39425335 [Contig_View]  DAB2 [Vega]
    Ensembl hg38 (Hinxton)ENSG00000153071 [Gene_View]  chr5:39371776-39425335 [Contig_View]  DAB2 [Vega]
    ICGC DataPortalENSG00000153071
    TCGA cBioPortalDAB2
    AceView (NCBI)DAB2
    Genatlas (Paris)DAB2
    WikiGenes1601
    SOURCE (Princeton)DAB2
    Genetics Home Reference (NIH)DAB2
    Genomic and cartography
    GoldenPath hg19 (UCSC)DAB2  -     chr5:39371776-39425335 -  5p13.1   [Description]    (hg19-Feb_2009)
    GoldenPath hg38 (UCSC)DAB2  -     5p13.1   [Description]    (hg38-Dec_2013)
    EnsemblDAB2 - 5p13.1 [CytoView hg19]  DAB2 - 5p13.1 [CytoView hg38]
    Mapping of homologs : NCBIDAB2 [Mapview hg19]  DAB2 [Mapview hg38]
    OMIM601236   
    Gene and transcription
    Genbank (Entrez)AF188298 AI739507 AK024965 AK092836 AK130136
    RefSeq transcript (Entrez)NM_001244871 NM_001343
    RefSeq genomic (Entrez)
    Consensus coding sequences : CCDS (NCBI)DAB2
    Cluster EST : UnigeneHs.696631 [ NCBI ]
    CGAP (NCI)Hs.696631
    Alternative Splicing GalleryENSG00000153071
    Gene ExpressionDAB2 [ NCBI-GEO ]   DAB2 [ EBI - ARRAY_EXPRESS ]   DAB2 [ SEEK ]   DAB2 [ MEM ]
    Gene Expression Viewer (FireBrowse)DAB2 [ Firebrowse - Broad ]
    SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
    GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
    BioGPS (Tissue expression)1601
    GTEX Portal (Tissue expression)DAB2
    Protein : pattern, domain, 3D structure
    UniProt/SwissProtP98082   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
    NextProtP98082  [Sequence]  [Exons]  [Medical]  [Publications]
    With graphics : InterProP98082
    Splice isoforms : SwissVarP98082
    PhosPhoSitePlusP98082
    Domaine pattern : Prosite (Expaxy)PID (PS01179)   
    Domains : Interpro (EBI)PH_dom-like    PTB/PI_dom   
    Domain families : Pfam (Sanger)PID (PF00640)   
    Domain families : Pfam (NCBI)pfam00640   
    Domain families : Smart (EMBL)PTB (SM00462)  
    Conserved Domain (NCBI)DAB2
    DMDM Disease mutations1601
    Blocks (Seattle)DAB2
    PDB (SRS)2LSW   
    PDB (PDBSum)2LSW   
    PDB (IMB)2LSW   
    PDB (RSDB)2LSW   
    Structural Biology KnowledgeBase2LSW   
    SCOP (Structural Classification of Proteins)2LSW   
    CATH (Classification of proteins structures)2LSW   
    SuperfamilyP98082
    Human Protein AtlasENSG00000153071
    Peptide AtlasP98082
    HPRD03139
    IPIIPI00179438   IPI00219298   IPI00954039   IPI00964260   IPI00964100   IPI00964896   IPI00965741   
    Protein Interaction databases
    DIP (DOE-UCLA)P98082
    IntAct (EBI)P98082
    FunCoupENSG00000153071
    BioGRIDDAB2
    STRING (EMBL)DAB2
    ZODIACDAB2
    Ontologies - Pathways
    QuickGOP98082
    Ontology : AmiGOpositive regulation of protein phosphorylation  protein binding  nucleolus  lysosomal membrane  plasma membrane  plasma membrane  clathrin-coated pit  focal adhesion  receptor-mediated endocytosis  apoptotic process  integrin-mediated signaling pathway  multicellular organism development  protein C-terminus binding  cell proliferation  positive regulation of epithelial to mesenchymal transition  positive regulation of pathway-restricted SMAD protein phosphorylation  protein transport  Wnt signaling pathway  clathrin-coated vesicle  positive regulation of cell migration  positive regulation of transforming growth factor beta receptor signaling pathway  clathrin-coated vesicle membrane  negative regulation of protein binding  positive regulation of proteasomal ubiquitin-dependent protein catabolic process  leading edge cell differentiation  clathrin adaptor activity  cargo receptor activity  negative regulation of apoptotic process  intracellular membrane-bounded organelle  positive regulation of endocytosis  negative regulation of transcription, DNA-templated  positive regulation of transcription, DNA-templated  SMAD binding  positive regulation of SMAD protein import into nucleus  negative regulation of androgen receptor signaling pathway  transforming growth factor beta receptor complex  extracellular exosome  negative regulation of canonical Wnt signaling pathway  negative regulation of canonical Wnt signaling pathway  negative regulation of protein localization to plasma membrane  positive regulation of Wnt signaling pathway, planar cell polarity pathway  positive regulation of clathrin-dependent endocytosis  positive regulation of early endosome to late endosome transport  
    Ontology : EGO-EBIpositive regulation of protein phosphorylation  protein binding  nucleolus  lysosomal membrane  plasma membrane  plasma membrane  clathrin-coated pit  focal adhesion  receptor-mediated endocytosis  apoptotic process  integrin-mediated signaling pathway  multicellular organism development  protein C-terminus binding  cell proliferation  positive regulation of epithelial to mesenchymal transition  positive regulation of pathway-restricted SMAD protein phosphorylation  protein transport  Wnt signaling pathway  clathrin-coated vesicle  positive regulation of cell migration  positive regulation of transforming growth factor beta receptor signaling pathway  clathrin-coated vesicle membrane  negative regulation of protein binding  positive regulation of proteasomal ubiquitin-dependent protein catabolic process  leading edge cell differentiation  clathrin adaptor activity  cargo receptor activity  negative regulation of apoptotic process  intracellular membrane-bounded organelle  positive regulation of endocytosis  negative regulation of transcription, DNA-templated  positive regulation of transcription, DNA-templated  SMAD binding  positive regulation of SMAD protein import into nucleus  negative regulation of androgen receptor signaling pathway  transforming growth factor beta receptor complex  extracellular exosome  negative regulation of canonical Wnt signaling pathway  negative regulation of canonical Wnt signaling pathway  negative regulation of protein localization to plasma membrane  positive regulation of Wnt signaling pathway, planar cell polarity pathway  positive regulation of clathrin-dependent endocytosis  positive regulation of early endosome to late endosome transport  
    Pathways : KEGGEndocytosis   
    REACTOMEP98082 [protein]
    REACTOME PathwaysR-HSA-8856828 [pathway]
    NDEx NetworkDAB2
    Atlas of Cancer Signalling NetworkDAB2
    Wikipedia pathwaysDAB2
    Orthology - Evolution
    OrthoDB1601
    GeneTree (enSembl)ENSG00000153071
    Phylogenetic Trees/Animal Genes : TreeFamDAB2
    HOVERGENP98082
    HOGENOMP98082
    Homologs : HomoloGeneDAB2
    Homology/Alignments : Family Browser (UCSC)DAB2
    Gene fusions - Rearrangements
    Fusion : MitelmanPAIP1/DAB2 [5p12/5p13.1]  [t(5;5)(p12;p13)]  
    Fusion: TCGAPAIP1 5p12 DAB2 5p13.1 OV
    Polymorphisms : SNP and Copy number variants
    NCBI Variation ViewerDAB2 [hg38]
    dbSNP Single Nucleotide Polymorphism (NCBI)DAB2
    dbVarDAB2
    ClinVarDAB2
    1000_GenomesDAB2 
    Exome Variant ServerDAB2
    ExAC (Exome Aggregation Consortium)DAB2 (select the gene name)
    Genetic variants : HAPMAP1601
    Genomic Variants (DGV)DAB2 [DGVbeta]
    DECIPHER (Syndromes)5:39371776-39425335  ENSG00000153071
    CONAN: Copy Number AnalysisDAB2 
    Mutations
    ICGC Data PortalDAB2 
    TCGA Data PortalDAB2 
    Broad Tumor PortalDAB2
    OASIS PortalDAB2 [ Somatic mutations - Copy number]
    Somatic Mutations in Cancer : COSMICDAB2  [overview]  [genome browser]  [tissue]  [distribution]  
    Mutations and Diseases : HGMDDAB2
    LOVD (Leiden Open Variation Database)Whole genome datasets
    LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
    LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
    BioMutasearch DAB2
    DgiDB (Drug Gene Interaction Database)DAB2
    DoCM (Curated mutations)DAB2 (select the gene name)
    CIViC (Clinical Interpretations of Variants in Cancer)DAB2 (select a term)
    intoGenDAB2
    NCG5 (London)DAB2
    Cancer3DDAB2(select the gene name)
    Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
    Diseases
    OMIM601236   
    Orphanet
    MedgenDAB2
    Genetic Testing Registry DAB2
    NextProtP98082 [Medical]
    TSGene1601
    GENETestsDAB2
    Huge Navigator DAB2 [HugePedia]
    snp3D : Map Gene to Disease1601
    BioCentury BCIQDAB2
    ClinGenDAB2
    Clinical trials, drugs, therapy
    Chemical/Protein Interactions : CTD1601
    Chemical/Pharm GKB GenePA27132
    Clinical trialDAB2
    Miscellaneous
    canSAR (ICR)DAB2 (select the gene name)
    Probes
    Litterature
    PubMed116 Pubmed reference(s) in Entrez
    GeneRIFsGene References Into Functions (Entrez)
    CoreMineDAB2
    EVEXDAB2
    GoPubMedDAB2
    iHOPDAB2
    REVIEW articlesautomatic search in PubMed
    Last year publicationsautomatic search in PubMed

    Search in all EBI   NCBI

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Sat Jan 21 16:34:51 CET 2017

    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.